Researchers at the University of Queensland are developing selective, small molecule inhibitors of haematopoietic prostaglandin D2 synthase for the treatment of asthma and allergic rhinitis.
Prostaglandin D2 is a well recognized proinflammatory modulator of asthma and allergic disease, making its bioactivity and synthesis well validated targets for therapeutic intervention.

UniQuest Contact: 

Mark Ashton

Executive Director, Intellectual Property Commercialisation
Mobile phone: 
+61 410 601 970
Work phone: 
+61 (7) 3365 4037